Therapy Explained

Recruiting The Body's own Immune Cells to Make Chemotherapy Work Better Without Making One Sick

The world is often transformed by simple ideas overlooked by thousands. Toxicity-Free Immuno-Chemotherapy uses such an idea.

Toxicity-Free chemo uses antidotes to the chemo agents during therapy so the body’s normal dividing cells aren’t killed like in ordinary chemo. This eliminates most side effects, and allows Toxicity-Free Chemo to preserve your body’s immune cells. The white blood immune neutrophil cells are then able to greatly increase the power of chemotherapy, making complete cancer eradication now possible!

For lung cancer patients conventional chemo extends life by as little as 1.35 months, but patients sacrificed their quality of life. Toxicity-Free Chemo is remarkable. It achieved long-term remission for every lung cancer victim who completed their therapy.

What Did the US FDA Think about This Therapy?

The United States FDA approved the first clinical trial 3 decades ago in a record-breaking four days. The current Toxicity-Free Chemo is in complete compliance with the FDA laws.

EXPERIENCE

In the initial Phase II clinical trial, all four terminal patients recovered and went onto long-term remissions. These patients had stage 4 breast, stage 3B NSC lung, and leukemic cancers. The longest survivor so far has gone over 20 years without her cancer recurring. The terminal leukemic patient went into complete remission after only three weekly Toxicity-Free Chemo treatments.

The metastases spread extensively to both lungs and liver of a colorectal cancer patient were shown to be visibly cleared in a CT scan after 4 weeks.

Hepatocellular carcinoma (liver) is uniformly fatal. Three of the four liver lobes of our patient cleared with Toxicity-Free Immuno-Chemotherapy and he opted to have the fourth lobe removed. The patient is alive today 12 years later.

Also see Testimonials.

We Know

Every patient and case is different. We would not expect everyone to respond the same.

But we have a higher percentage of results that were markedly faster, were less painful, and produced longer lasting remissions than the therapies known as “standard of care.”